Last reviewed · How we verify
Ticagrelor 60mg
Ticagrelor 60mg, marketed by Fundacin Biomedica Galicia Sur, is a well-established drug in its therapeutic class. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of reported revenue data, which may affect investment and market valuation.
At a glance
| Generic name | Ticagrelor 60mg |
|---|---|
| Also known as | Brillique, Brilinta 60 mg, High platelet reactivity patients, Brilique, Brillinta |
| Sponsor | Fundacin Biomedica Galicia Sur |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
- Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI (PHASE4)
- Brilinta Clinical Experience Investigation
- TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (PHASE4)
- Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold (PHASE4)
- A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |